Skip to main content

Table 1 LTT results of patients who had DHR to a combination therapy

From: EAACI/ESCD Skin Allergy Meeting 2017 (SAM 2017)

Total pos. LTT Pos. LTT/% Pos. LTT/% Pos. LTT/%
AMX/CLA Amoxicillin (AMX) Clavulanic acid (CLA) Both
n = 115 64 (56%) 12 (10%) 39 (34%)
TMP/SMX Trimethoprim (TMP) Sulfamethoxazole (SMX) Both
n = 37 4 (11%) 16 (43%) 17 (46%)
PIP/TZB Piperacillin (PIP) Tazobactam (TZB) Both
n = 21 7 (33%) 7 (33%) 7 (33%)
Sulfasalazine Sulfapyridine 5-Aminosalicylic acid (5-ASA) Both
n = 10 6 (60%) 0 (0%) 4 (40%)
Total n = 183 93 (33–60%) 23 (0–33%) 67 (33–46%)